| | Characteristics | Total (%) |
| | Gender | | | Male, (%) | 159 (85.9) | | Female, (%) | 26 (14.1) | | Median age (years) | | | <60 years, (%) | 106 (57.3) | | ≥60 years, (%) | 79 (42.7) | | AFP (ng/ml) | 79.82 (7.59, 1996.50) | | ≤20 ng/ml, (%) | 68 (36.8%) | | ≤400 ng/ml, (%) | 118 (63.8%) | | ALT (U/l), median (IQR) | 37.00 (19.00, 65.85) | | AST (U/l), median (IQR) | 51.00 (35.00, 89.00) | | HBV infection | | | Negative, (%) | 32 (17.3) | | Positive, (%) | 153 (82.7) | | HCV infection | | | Negative, (%) | 161 (87.0%) | | Positive, (%) | 24 (13.0%) | | Tumor size | | | ≤5 cm, (%) | 121 (65.4) | | >5 cm, (%) | 64 (34.6) | | Clinical stage | | | I, (%) | 32 (17.3) | | II, (%) | 91 (49.2) | | III, (%) | 29 (15.7) | | IV, (%) | 33 (17.8) | | Tumor differentiation | | | I, (%) | 35 (18.9) | | II, (%) | 107 (57.8) | | III, (%) | 43 (23.2) | | rs1169288 | | | AA, (%) | 58 (31.4) | | AC, (%) | 95 (51.3) | | CC, (%) | 32 (17.3) | | rs2464196 | | | GG, (%) | 42 (22.7) | | GA, (%) | 98 (53.0) | | AA, (%) | 45 (24.3) | | rs1169310 | | | CC, (%) | 40 (21.6) | | CT, (%) | 101 (54.6) | | TT, (%) | 44 (23.8) |
|
|
